.png){kind=icon}
.png){kind=icon}
Return
Inclisiran—will it fulfill its promise?
.png){kind=icon}
PRE
AI
S
F
F
DOI：10.1016/j.numecd.2026.104848.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Inclisiran reduces LDL-C in high-risk primary and secondary prevention patients. • Iinclisiran is also effective in HeFH and HoFH populations. • Twice-yearly dosing may improve long-term adherence versus oral therapies. • Safety profile is favorable across major clinical trials. • Ongoing trials will determine impact on ASCVD clinical outcomes.
Journal
N
IF:
0
Papers:
307
Citations:
0
Organization
Cited Papers